




Junaxo

==== JNX3001 AS A TREATMENT FOR PARKINSON'S DISEASE ====

JNX3001 is a therapy based on a disaccharide known as trehalose. JNX3001 has been designed to target α -synuclein, the protein that drives pathology in people with Parkinson's disease (PD) and shows efficacy in several preclinical models PD including non-human primate. Trehalose itself, is Generally Regarded as Safe in US and EU and JNX3001 can be immediately advanced to clinical trial in PD for use as a Medical Food. Peak revenues are estimated at US\$170M p.a.



==== THE OPPORTUNITY ====

PD – The problem

PD is a neurodegenerative disorder affecting as many as a million people in the US, approximately 60,000 new cases are diagnosed each year. PD is characterised by accumulation of a toxic protein, alpha-synuclein (aSyn) in subsequent loss of dopaminergic neurons in the substantia nigra, and elsewhere in the brain, which leads to motor and non-motor symptoms. The cardinal motor symptoms are tremor, rigidity, slowness of movement, and postural instability.

There is currently no cure for PD but medications, surgery and multidisciplinary management can provide some relief from the symptoms. The most widely-used treatments of PD are dopamine replacement therapies although the effectiveness of such treatments diminishes significantly with time and leave many non-motor symptoms untreated. A therapy that could slow disease progression would represent a breakthrough therapy and address an important unmet clinical need.

JNX3001 – The solution

JNX3001 is based upon trehalose, a disaccharide that is already approved for human consumption as a food additive. In animals, trehalose can provide neuroprotection in a variety of animal models of PD and, indeed, other neurodegenerative diseases.

Junaxo's development of JNX3001 has been led by Dr Brotchie, a world-renowned expert in PD who also holds an academic position at the University Health Network, Toronto. Following non-dilutive investment of US\$1.2M from the Michael J Fox Foundation, we performed extensive research to develop JNX3001, including a pivotal study in non-human primates, expressing a mutated human form of aSyn. Dr Brotchie demonstrated that the disease modifying effects of JNX3001 translated from rodent to non-human primates where JNX3001 significantly increased dopamine level in the striatum. Furthermore, Dr Brotchie characterised the exposure of JNX3001 needed to achieve these effects

JNX3001 is approved for human consumption and could quickly be progressed into Phase II clinical studies.

==== THE INVESTMENT ====

Junaxo Inc. is a drug development company located in Toronto, Canada. Junaxo is currently seeking an investment of US\$6.5M that will allow us to evaluate the effect of JNX3001 in people with PD in a Phase I and then a Phase II clinical study. After these studies, JNX3001 would be immediately progressed to market as a Medical Food.